Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

To assess the safety and immunologic impact of inhibiting interferon‐γ (IFNγ) with AMG 811, a human IgG1 monoclonal antibody against IFNγ, in patients with systemic lupus erythematosus (SLE).

[1]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Viswanath Devanarayan,et al.  Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. , 2011, Journal of pharmaceutical and biomedical analysis.

[3]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[4]  K. Kalunian,et al.  Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study , 2013, Arthritis and rheumatism.

[5]  C. Heusser,et al.  Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells , 1993, The Journal of experimental medicine.

[6]  G. Trinchieri,et al.  Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. , 1998, Arthritis and rheumatism.

[7]  C. Lam,et al.  Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[8]  H. Mcdevitt,et al.  In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon , 1987, The Journal of experimental medicine.

[9]  X. Cui,et al.  Statistical tests for differential expression in cDNA microarray experiments , 2003, Genome Biology.

[10]  T. Takeuchi,et al.  Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. , 2000, Cytokine.

[11]  R. Maciuca,et al.  Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. , 2012, Arthritis and rheumatism.

[12]  Jonathan D. Hron,et al.  Type I IFN Protects Against Murine Lupus1 , 2004, The Journal of Immunology.

[13]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[14]  Wentian Li,et al.  Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus Erythematosus , 2006, PLoS medicine.

[15]  Mimi Y. Kim,et al.  Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.

[16]  P. Gregersen,et al.  Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. , 2009, Arthritis and rheumatism.

[17]  D. Symmons,et al.  Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus , 1988 .

[18]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[19]  D. Balomenos,et al.  Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. , 1998, The Journal of clinical investigation.

[20]  D. Balomenos,et al.  Interferon-g is Required for Lupus-like Disease and Lymphoaccumulation in MRL-lpr Mice , 2022 .

[21]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[22]  K. Akashi,et al.  Involvement of interferon‐γ and macrophage colony‐stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults , 1994, British journal of haematology.

[23]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[24]  J. Moslehi,et al.  Roles of interferon-gamma and interleukin-4 in murine lupus. , 1997, The Journal of clinical investigation.

[25]  Virginia Pascual,et al.  Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures , 2014, Arthritis & rheumatology.

[26]  D. Wendling,et al.  Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. , 1993, The Journal of rheumatology.

[27]  L. Joosten,et al.  Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[28]  Christine A. Biron,et al.  Interferon α/β-mediated inhibition and promotion of interferon γ: STAT1 resolves a paradox , 2000, Nature Immunology.

[29]  R. N. Kackar,et al.  Approximations for Standard Errors of Estimators of Fixed and Random Effects in Mixed Linear Models , 1984 .

[30]  W. Graninger,et al.  Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. , 1991, The Journal of rheumatology.

[31]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[32]  A. Horiuchi,et al.  Serum level of interferon-gamma in autoimmune diseases. , 1991, The Tohoku journal of experimental medicine.

[33]  L. Lenz,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[34]  P. Kiener,et al.  Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[35]  N. Kamatani,et al.  Excessive Production of IFN-γ in Patients with Systemic Lupus Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating Factor/TNF Ligand Superfamily-13B1 , 2008, The Journal of Immunology.

[36]  K O Kong,et al.  Enhanced expression of interferon‐inducible protein‐10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus , 2008, Clinical and experimental immunology.

[37]  M. Aringer,et al.  Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. , 2009, Arthritis and rheumatism.

[38]  C. Cheadle,et al.  Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases , 2012, Proceedings of the National Academy of Sciences.

[39]  J. Moslehi,et al.  Roles of Interferon-g and Interleukin-4 in Murine Lupus , 2013 .